Copertina

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Neeta B. Amin, Robert Frederich, Nikolaos Tsamandouras, Amina Z. Haggag, Tilman Schuster, Witold Zmuda, Alexandra Palmer, Szilard Vasas, Gina Buckley, Timothy R. Smith, Sarah J. DuBrava, Qi Zhu, Margot Johnson
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Diabetes, Obesity and Metabolism
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies
di: Clare Buckeridge, et al.
Pubblicazione: (2024)

Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
di: Mona Abdel‐Bary, et al.
Pubblicazione: (2025)

Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
di: Jason Zupec, et al.
Pubblicazione: (2025)

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
di: Carel W. le Roux, et al.
Pubblicazione: (2024)

Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon‐like peptide‐1 agonists
di: Naadir Jamal, et al.
Pubblicazione: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
di: Yunwen Xu, et al.
Pubblicazione: (2025)

The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
di: Victoria Wen Wei Ng, et al.
Pubblicazione: (2024)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
di: David C. Klonoff, et al.
Pubblicazione: (2024)

Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
di: Deep Dutta, et al.
Pubblicazione: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
di: Darren Lau, et al.
Pubblicazione: (2024)

Expanding the discussion on airway management with glucagon‐like peptide‐1 receptor agonist use
di: Jenny E. Pennycuff, et al.
Pubblicazione: (2025)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
di: W. Timothy Garvey, et al.
Pubblicazione: (2024)

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
di: Yu‐Nan Huang, et al.
Pubblicazione: (2024)

Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
di: Jessica Van Laren, et al.
Pubblicazione: (2026)

Gastric ultrasound and mitigating risk of glucagon‐like peptide‐1 receptor agonists: a reply
di: Peter C.‐A. Kam, et al.
Pubblicazione: (2024)

Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
Pubblicazione: (2025)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
di: Fu‐Shun Yen, et al.
Pubblicazione: (2025)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
di: Aakash Desai, et al.
Pubblicazione: (2024)

Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
di: Faisal I. Almohaileb, et al.
Pubblicazione: (2025)

Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
di: Abraish Ali, et al.
Pubblicazione: (2025)

Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes
di: Yu‐Ting Yu, et al.
Pubblicazione: (2026)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
di: Iskandar Idris
Pubblicazione: (2024)

Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
di: Michael G. Buontempo, et al.
Pubblicazione: (2025)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
di: Julio Rosenstock, et al.
Pubblicazione: (2025)

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
di: Kariem El‐Boghdadly, et al.
Pubblicazione: (2025)

Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
di: Chia‐Ming Lin, et al.
Pubblicazione: (2025)

Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis
di: Pedro Robson Costa Passos, et al.
Pubblicazione: (2024)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
di: Conner E. Johnson, et al.
Pubblicazione: (2024)

Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis
di: Gianmaria Salvio, et al.
Pubblicazione: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
di: Karen L. Jones, et al.
Pubblicazione: (2024)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
di: Hirotaka Watada
Pubblicazione: (2024)

Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
di: Sara Berg, et al.
Pubblicazione: (2025)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
di: Filip K. Knop, et al.
Pubblicazione: (2024)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
di: Jincheng Shen, et al.
Pubblicazione: (2025)

The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial
di: Kelli M. Richardson, et al.
Pubblicazione: (2025)

Chemerin loss‐of‐function attenuates glucagon‐like peptide‐1 secretion in exercised obese mice
di: Qilong Zhang, et al.
Pubblicazione: (2025)

The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study
di: Zhiyuan Cheng, et al.
Pubblicazione: (2024)

Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
di: Mehmet Kanbay, et al.
Pubblicazione: (2024)

Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial
di: Manu V. Chakravarthy, et al.
Pubblicazione: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
di: Irl B. Hirsch, et al.
Pubblicazione: (2024)